Current and emerging pharmacotherapy for respiratory syncytial virus (RSV) infection in infants

Area of Science:

• Virology and Immunology
• Pharmacology and Therapeutics

Background:

• Respiratory syncytial virus (RSV) is a prevalent respiratory pathogen with significant global health and economic impact.
• Current prevention and treatment options for RSV infection are limited, highlighting an unmet medical need.

Purpose of the Study:

• To review the characteristics of RSV and the developmental status of novel pharmacological interventions.
• To discuss strategies for overcoming limitations of existing treatments like palivizumab and ribavirin.

Main Methods:

• In-depth exploration of RSV structure and identification of potential therapeutic targets.
• Development of immunization strategies for infants, including maternal immunization and advanced monoclonal antibodies.
• Evaluation of vaccine candidates for different age groups and immunocompromised individuals, alongside novel antiviral drug discovery targeting viral proteins.

Main Results:

• Identification of new pharmacological measures, including advanced monoclonal antibodies and vaccines tailored for specific populations.
• Development of antiviral drugs targeting key RSV proteins involved in host cell entry and viral replication.
• Emerging evidence suggests some new preparations are effective and safe, though further studies are required.

Conclusions:

• Significant progress has been made in developing novel strategies for RSV prevention and treatment.
• Future prospects for managing RSV infection are improving due to advancements in vaccines and antiviral therapies.
• Ongoing research is crucial to validate the safety and efficacy of these promising new interventions.